Biotech

All Articles

Pfizer takes $230M reached after axing neglected DMD gene therapy

.Pfizer's period 3 Duchenne muscle dystrophy (DMD) gene treatment breakdown has actually gone a $230...

AC Immune sees 'spots' potential in Alzheimer's medicine records

.After greater than twenty years of focus on neurodegenerative diseases, Swiss biotech a/c Immune sy...

GSK goes down ph. 2 HPV injection over shortage of best-in-class prospective

.GSK has actually ditched a period 2 individual papillomavirus (HPV) vaccination from its own pipeli...

OS Treatments refiles $6M IPO to fund HER2 medicine, preclinical ADCs

.OS Therapies are going to detail on the NYSE American sell swap this morning by means of a $6.4 mil...

ALX's fizzling CD47 action rate sends out supply spiraling down

.ALX Oncology's period 2 gastric cancer cells reaction rate has deteriorated. After seeing its own C...

Ionis axes eye disease from targets of Roche-partnered possibility after records dissatisfy

.An Additional of Ionis Pharmaceuticals' crucial midphase readouts has actually fallen short of expe...

Biogen's CEO claimed no dangerous sell 2023. He's ready to become bold

.While Biogen's pharma peers are looking for late-stage assets along with little danger, CEO Chris V...

Instil refills pipe in $2B biobucks cope with ImmunOnco

.Instil Bio has been actually a biotech seeking a pipeline after it junked its own lead properties o...

Biogen leaves Denali Alzheimer's collab

.Biogen has restored liberties to an early Alzheimer's illness plan to Denali Therapeutics, going ou...

Takeda touches brand-new head people oncology service-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our summary of considerable management hirings, shootings an...